

Supporting Information

**Synthesis of α -Keto Imides through Copper-Catalyzed Oxidation of *N*-Sulfonyl
Ynamides**

Xin Liu,^{a,‡} Zhi-Xin Zhang,^{a,‡} Bo Zhou,^a Ze-Shu Wang,^a Ren-Hua Zheng,^{*b} and
Long-Wu Ye^{*a,c}

^aCollaborative Innovation Center of Chemistry for Energy Material, State Key
Laboratory of Physical Chemistry of Solid Surfaces and Key Laboratory for Chemical
Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen
University, Xiamen 361005, China

^bSchool of Pharmaceutical and Chemical Engineering, Taizhou University, Taizhou
318000, China

^cState Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic
Chemistry, Chinese Academy of Sciences, Shanghai 200032, China


Content	Page number
General	2
Preparation of Starting Materials	3
General Procedure: Copper Catalysis	4
¹ H and ¹³ C NMR Spectra	14

General Information. Ethyl acetate (ACS grade), hexanes (ACS grade), methanol (ACS grade) and anhydrous DCE (ACS grade) were obtained commercially and used without further purification. Toluene and tetrahydrofuran were purified according to standard methods unless otherwise noted. Commercially available reagents were used without further purification. Reactions were monitored by thin layer chromatography (TLC) using silicycle pre-coated silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). Infrared spectra were recorded on a Nicolet AVATER FTIR330 spectrometer as thin film and are reported in reciprocal centimeter (cm^{-1}). Mass spectra were recorded with Micromass QTOF₂ Quadrupole/Time-of-Flight Tandem mass spectrometer using electron spray ionization.


¹H NMR spectra were recorded on a Bruker AV-400 spectrometer and a Bruker AV-500 spectrometer in chloroform-d₃. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data is being reported as (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, brs = broad singlet, coupling constant(s) in Hz, integration).

¹³C NMR spectra were recorded on a Bruker AV-400 spectrometer and a Bruker AV-500 spectrometer in chloroform-d₃. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard.

The data of the following ynamides **1a-d**, **1f-m** and **1o** were reported in our previous work.¹⁻³




N-(4-fluorophenyl)-4-methyl-*N*-(phenylethynyl)benzenesulfonamide (**1e**)




Compound **1e** was prepared in 65% yield (237.3 mg) according to the above known procedure.⁴ Pale yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, *J* = 8.5 Hz, 2H), 7.38 – 7.26 (m, 9H), 7.01 – 6.95 (m, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.3 (d, *J* = 248.0 Hz), 145.0, 138.8, 133.5 (d, *J* = 8.0 Hz), 132.9, 129.5, 129.1, 128.3, 128.2, 126.2, 118.6, 115.5 (d, *J* = 22.0 Hz), 82.6, 69.3, 21.6; IR (neat): 3067, 2923, 2243, 1598, 1509, 1374, 1176, 837, 692, 581; HRESIMS Calcd for [C₂₁H₁₆FNNaO₂S]⁺ (*M* + Na⁺) 388.0778, found 388.0779.

N-methyl-2-nitro-*N*-(phenylethynyl)benzenesulfonamide (**1n**)




Compound **1n** was prepared in 58% yield (183.3 mg) according to the above known procedure.¹ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (dd, *J* = 1.2 Hz, *J* = 7.2 Hz, 1H), 7.80 – 7.63 (m, 3H), 7.39 – 7.31 (m, 2H), 7.30 – 7.22 (m, 3H), 3.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 147.7, 134.8, 131.7, 131.3, 131.2, 129.5, 128.1, 128.0, 124.2, 121.8, 82.1, 70.0, 39.5; IR (neat): 3021, 2933, 2237, 1360, 1163, 960, 783, 757, 693, 551, 516; HRESIMS Calcd for [C₁₅H₁₂N₂NaO₄S]⁺ (*M* + Na⁺) 339.0410, found 339.0412.



General procedure for the synthesis of α-keto imides **2**:

Cu(CH₃CN)₄PF₆ (0.02 mmol, 7.5 mg) was added to a mixture of the ynamide **1** (0.20 mmol) and 8-methylquinoline *N*-oxide **3d** (95.5 mg, 0.60 mmol) in DCE (4.0 mL) at room temperature. Then, the reaction mixture was stirred at 80 °C and the progress of the reaction was monitored by TLC. The reaction typically took 5 h. Upon completion, the mixture was concentrated and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired α-keto imide **2**.


N-methyl-2-oxo-2-phenyl-*N*-tosylacetamide (**2a**)



Compound **2a** was prepared in 86% yield (81.9 mg) according to the general procedure (Table 2, entry 1). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J*

= 7.2 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H), 7.67 – 7.63 (m, 1H), 7.57 – 7.50 (m, 2H), 7.39 (d, J = 8.0 Hz, 2H), 3.24 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 188.0, 167.2, 145.9, 134.4, 133.4, 132.7, 130.1, 129.6, 128.8, 128.3, 30.7, 21.7; IR (neat): 2917, 2849, 1681(s), 1372, 1232, 1166, 947, 717, 664, 594; HRESIMS Calcd for $[\text{C}_{16}\text{H}_{15}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 340.0614, found 340.0615.


2-oxo-*N*,2-diphenyl-*N*-tosylacetamide (**2b**)



2b

Compound **2b** was prepared in 89% yield (101.3 mg) according to the general procedure (Table 2, entry 2). Pale yellow solid (mp 152-154 °C). ^1H NMR (500 MHz, CDCl_3) δ 7.93 (d, J = 7.5 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.66 – 7.62 (m, 1H), 7.54 – 7.49 (m, 2H), 7.43 – 7.32 (m, 5H), 7.13 (d, J = 7.5 Hz, 2H), 2.47 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.6, 166.7, 145.9, 134.6, 134.1, 133.5, 132.7, 130.6, 130.2, 129.7, 129.6, 129.4, 129.0, 128.9, 21.7; IR (neat): 2924, 2853, 1682(s), 1372, 1230, 1175, 1088, 695, 665, 600; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 402.0770, found 402.0773.

N-allyl-2-oxo-2-phenyl-*N*-tosylacetamide (**2c**)




2c

Compound **2c** was prepared in 74% yield (76.2 mg) according to the general procedure (Table 2, entry 3). Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 8.00 – 7.85 (m, 4H), 7.68 – 7.60 (m, 1H), 7.58 – 7.48 (m, 2H), 7.41 – 7.33 (m, 2H), 5.83 –

5.67 (m, 1H), 5.25 (d, $J = 17.0$ Hz, 1H), 5.16 (d, $J = 10.0$ Hz, 1H), 4.35 (d, $J = 5.5$ Hz, 2H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 187.7, 166.9, 145.8, 134.4(2), 134.3(9), 132.8, 130.6, 130.0, 129.7, 128.8, 128.6, 119.5, 47.2, 21.7; IR (neat): 3039, 2923, 1682(s), 1596, 1372, 1153, 821, 791, 716, 589; HRESIMS Calcd for $[\text{C}_{18}\text{H}_{17}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 366.0770, found 366.0772.


2-oxo-2-phenyl-*N*-(*p*-tolyl)-*N*-tosylacetamide (2d)



2d

Compound **2d** was prepared in 91% yield (107.4 mg) according to the general procedure (Table 2, entry 4). Pale yellow solid (mp 164-166 °C). ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 7.6$ Hz, 2H), 7.76 (d, $J = 8.0$ Hz, 2H), 7.64 – 7.59 (m, 1H), 7.52 – 7.46 (m, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.00 (d, $J = 8.0$ Hz, 2H), 2.45 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.6, 166.7, 145.7, 140.5, 134.5, 134.1, 132.7, 130.7, 130.2, 130.1, 129.7, 129.5, 129.0, 128.8, 21.7, 21.2; IR (neat): 3066, 2923, 1682(s), 1596, 1371, 1172, 957, 715, 655, 590; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{19}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 416.0927, found 416.0926.


***N*-(4-fluorophenyl)-2-oxo-2-phenyl-*N*-tosylacetamide (2e)**



2e

Compound **2e** was prepared in 83% yield (99.0 mg) according to the general procedure (Table 2, entry 5). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, J = 7.2 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.67 – 7.62 (m, 1H), 7.56 – 7.49 (m, 2H), 7.38 – 7.30 (m, 3H), 7.17 – 7.12 (m, 1H), 6.93 – 6.87 (m, 2H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.3, 166.5, 162.6 (d, J = 248.0 Hz), 146.2, 134.7, 133.8, 132.5, 130.4 (d, J = 9.0 Hz), 129.8, 129.6, 129.0, 126.4 (d, J = 3.0 Hz), 118.2, 118.0, 117.5 (d, J = 20.0 Hz), 21.7; IR (neat): 3069, 2924, 1682(s), 1597, 1373, 1174, 958, 714, 656, 590; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{16}\text{FNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 420.0676, found 420.0679.


2-oxo-*N*-phenyl-2-(*p*-tolyl)-*N*-tosylacetamide (**2f**)



2f

Compound **2f** was prepared in 87% yield (102.7 mg) according to the general procedure (Table 2, entry 6). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, J = 7.2 Hz, 2H), 7.76 (d, J = 7.6 Hz, 2H), 7.44 – 7.26 (m, 7H), 7.14 – 7.11 (m, 2H), 2.45 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.2, 166.7, 145.8, 145.7, 134.1, 133.5, 130.5, 130.2, 130.1, 129.7, 129.6, 129.3, 129.0, 21.8, 21.7; IR (neat): 3066, 2923, 1678(s), 1605, 1372, 1177, 1033, 694, 669, 591; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{19}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 416.0927, found 416.0925.


2-(4-methoxyphenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (**2g**)



2g

Compound **2g** was prepared in 82% yield (100.7 mg) according to the general procedure (Table 2, entry 7). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.40 – 7.32 (m, 5H), 7.13 (d, J = 6.8 Hz, 2H), 6.98 – 6.93 (m, 2H), 3.87 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.2, 166.8, 164.7, 145.7, 134.2, 133.6, 132.0, 130.5, 130.1, 129.7, 129.3, 129.0, 125.6, 114.3, 55.6, 21.7; IR (neat): 3068, 2935, 1668(s), 1598, 1371, 1172, 1030, 816, 695, 667; HRESIMS Calcd for $[\text{C}_{22}\text{H}_{19}\text{NNaO}_5\text{S}]^+$ ($\text{M} + \text{Na}^+$) 432.0876, found 432.0876.


2-(4-fluorophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (**2h**)



2h

Compound **2h** was prepared in 85% yield (101.3 mg) according to the general procedure (Table 2, entry 8). Pale yellow solid (mp 159-161 °C). ^1H NMR (400 MHz, CDCl_3) δ 7.99 – 7.94 (m, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.44 – 7.32 (m, 5H), 7.23 – 7.17 (m, 2H), 7.12 (d, J = 7.6 Hz, 2H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 186.0, 166.5 (d, J = 256.0 Hz), 166.4, 146.0, 133.9, 133.4, 132.4 (d, J = 10.0 Hz), 130.5, 130.2, 129.8, 129.5, 129.2, 129.0, 116.3 (d, J = 23.0 Hz), 21.7; IR (neat): 3070, 2925, 1682(s), 1598, 1372, 1237, 1033, 957, 669, 590; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{16}\text{FNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 420.0676, found 420.0675.


2-(4-chlorophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (**2i**)



2i

Compound **2i** was prepared in 82% yield (101.8 mg) according to the general procedure (Table 2, entry 9). Pale yellow solid (mp 157-159 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, *J* = 8.4 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.44 – 7.31 (m, 5H), 7.12 (d, *J* = 7.2 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.5, 166.3, 146.0, 133.8, 133.3, 132.3, 131.5, 130.9, 130.4, 130.2, 130.0, 129.8, 129.5, 129.0, 21.7; IR (neat): 3068, 2927, 1676(s), 1590, 1372, 1173, 1034, 759, 666, 579; HRESIMS Calcd for [C₂₁H₁₆ClNNaO₄S]⁺ (M + Na⁺) 436.0381, found 436.0380.


2-(4-bromophenyl)-2-oxo-*N*-phenyl-*N*-tosylacetamide (**2j**)



2j

Compound **2j** was prepared in 79% yield (108.5 mg) according to the general procedure (Table 2, entry 10). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 2H), 7.44 – 7.31 (m, 5H), 7.11 (d, *J* = 7.2 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.5, 166.3, 146.0, 133.9, 133.4, 132.4, 131.6, 130.9, 130.5, 130.3, 130.1, 129.8, 129.5, 129.0, 21.7; IR (neat): 3066, 2924, 1682(s), 1588, 1372, 1174, 957, 753, 665, 578; HRESIMS Calcd for [C₂₁H₁₆BrNNaO₄S]⁺ (M + Na⁺) 479.9876, found 479.9877.


(*E*)-2-oxo-*N*,4-diphenyl-*N*-tosylbut-3-enamide (**2k**)



2k

Compound **2k** was prepared in 80% yield (97.3 mg) according to the general procedure (Table 2, entry 11). Orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 16.4 Hz, 1H), 7.58 – 7.54 (m, 2H), 7.48 – 7.38 (m, 6H), 7.35 (d, J = 8.0 Hz, 2H), 7.18 – 7.14 (m, 2H), 6.83 (d, J = 16.4 Hz, 1H), 2.48 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.0, 166.4, 148.5, 145.8, 134.3, 133.8(0), 133.7(5), 131.6, 130.5, 130.2, 129.7, 129.4, 129.1(1), 129.0(6), 128.9, 122.4, 21.8; IR (neat): 3063, 2924, 1681(s), 1596, 1372, 1174, 1088, 814, 694, 584; HRESIMS Calcd for $[\text{C}_{24}\text{H}_{20}\text{NaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 428.0927, found 428.0928.


***N*-(methylsulfonyl)-2-oxo-*N*,2-diphenylacetamide (2l)**



2l

Compound **2l** was prepared in 86% yield (78.3 mg) according to the general procedure (Table 2, entry 12). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, J = 7.2 Hz, 2H), 7.67 – 7.61 (m, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.49 – 7.45 (m, 3H), 7.39 – 7.35 (m, 2H), 3.40 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 187.9, 167.1, 134.9, 133.5, 132.3, 130.4, 130.0, 129.8 (4), 129.7 (8), 128.9, 41.2; IR (neat): 2930, 1693(s), 1596, 1369, 1180, 973, 769, 715, 694, 597; HRESIMS Calcd for $[\text{C}_{15}\text{H}_{13}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 326.0457, found 326.0454.


***N*-((4-bromophenyl)sulfonyl)-2-oxo-*N*,2-diphenylacetamide (2m)**



2m

Compound **2m** was prepared in 80% yield (106.6 mg) according to the general procedure (Table 2, entry 13). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, $J = 7.6$ Hz, 2H), 7.76 – 7.60 (m, 5H), 7.54 – 7.49 (m, 2H), 7.45 – 7.36 (m, 3H), 7.14 (d, $J = 7.2$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.4, 166.4, 136.0, 134.8, 133.1, 132.5, 132.4, 130.4(4), 130.4(2), 130.3(9), 130.1, 129.6, 129.0; IR (neat): 3091, 2924, 1695(s), 1376, 1177, 1009, 747, 610, 598, 557; HRESIMS Calcd for $[\text{C}_{20}\text{H}_{14}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 465.9719, found 465.9723.


***N*-methyl-*N*-((2-nitrophenyl)sulfonyl)-2-oxo-2-phenylacetamide (2n)**



2n

Compound **2n** was prepared in 93% yield (97.2 mg) according to the general procedure (Table 2, entry 14). Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 8.31 – 8.22 (m, 1H), 7.91 (d, $J = 7.5$ Hz, 2H), 7.85 – 7.79 (m, 3H), 7.69 – 7.64 (m, 1H), 7.55 – 7.49 (m, 2H), 3.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.6, 166.8, 148.4, 135.3, 135.1, 132.5, 132.2, 132.0, 131.0, 129.8, 129.0, 124.7, 32.4; IR (neat): 3065, 2924, 1789(s), 1696(s), 1396, 1239, 1124, 1032, 722, 656; HRESIMS Calcd for $[\text{C}_{15}\text{H}_{12}\text{N}_2\text{NaO}_6\text{S}]^+$ ($\text{M} + \text{Na}^+$) 371.0308, found 371.0304.

1-(2-oxooxazolidin-3-yl)-2-phenylethane-1,2-dione (2o)




2o

Compound **2o** was prepared in 66% yield (43.4 mg) according to the general procedure (Table 2, entry 15). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.91 –


7.86 (m, 2H), 7.68 – 7.62 (m, 1H), 7.55 – 7.48 (m, 2H), 4.60 (t, $J = 8.0$ Hz, 2H), 4.17 (t, $J = 8.4$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 187.8, 166.5, 153.1, 134.8, 132.4, 129.3, 129.0, 64.0, 40.9; IR (neat): 3099, 2924, 1686(s), 1545, 1377, 1229, 945, 734, 716, 604; HRESIMS Calcd for $[\text{C}_{11}\text{H}_9\text{NNaO}_4]^+$ ($\text{M} + \text{Na}^+$) 242.0424, found 242.0425.

2-hydroxy-*N*,2-diphenyl-*N*-tosylacetamide (**4a**)



Compound **4a** was prepared in 55% yield (41.9 mg, 0.2 mmol scale) according to the known procedure (Scheme 2, entry 1).⁵ Pale yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 7.91 (d, $J = 8.0$ Hz, 2H), 7.47 – 7.40 (m, 1H), 7.38 (d, $J = 8.0$ Hz, 2H), 7.33 – 7.23 (m, 3H), 7.20 – 7.15 (m, 2H), 6.90 – 6.76 (m, 2H), 6.73 (d, $J = 7.5$ Hz, 2H), 4.79 (s, 1H), 3.78 (s, 1H), 2.49 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.0, 145.5, 137.2, 135.4, 133.9, 130.2, 129.5, 129.3, 129.2, 128.8, 128.7, 127.5, 73.3, 21.7; IR (neat): 3477, 3066, 2925, 1702(s), 1489, 1365, 1172, 1087, 696, 569, 548; HRESIMS Calcd for $[\text{C}_{21}\text{H}_{19}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 404.0927, found 404.0929.

2-hydroxy-*N*,2-diphenyl-*N*-tosylpent-4-enamide (**5a**)



Compound **5a** was prepared in 79% yield (66.6 mg, 0.2 mmol scale) according to the known procedure (Scheme 2, entry 2).⁶ Yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.85 (d, $J = 8.4$ Hz, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.29 – 7.23 (m, 1H), 7.19 – 7.13 (m, 1H), 7.11 – 7.03 (m, 4H), 6.84 – 6.79 (m, 2H), 6.67 (d, $J = 7.2$ Hz, 2H), 5.69 – 5.57 (m, 1H), 5.15 – 5.07 (m, 2H), 3.30 (s, 1H), 2.90 (dd, $J = 6.8$ Hz, $J = 14.0$ Hz, 1H), 2.50 (dd, $J = 7.6$ Hz, $J = 14.0$ Hz, 1H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.4, 144.9, 140.7, 135.6, 134.3, 131.9, 131.3, 129.3(2), 129.3(0), 129.2, 128.2,



128.1, 127.6, 124.5, 120.7, 79.4, 44.7, 21.6; IR (neat): 3505, 3069, 2922, 1697(s), 1596, 1490, 1363, 1169, 1088, 696, 579, 551; HRESIMS Calcd for $[C_{24}H_{23}NNaO_4S]^+$ (M + Na⁺) 444.1240, found 444.1243.




References:

1. Pan, F.; Li, X.-L.; Chen, X.-M.; Shu, C.; Ruan, P.-P.; Shen, C.-H.; Lu, X.; Ye, L.-W. *ACS Catal.* **2016**, 6, 6055.
2. Zhou, A.-H.; He, Q.; Shu, C.; Yu, Y.-F.; Liu, S.; Zhao, T.; Zhang, W.; Lu, X.; Ye, L.-W. *Chem. Sci.* **2015**, 6, 1265.
3. Li, L.; Shu, C.; Zhou, B.; Yu, Y.-F.; Xiao, X.-Y.; Ye, L.-W. *Chem. Sci.* **2014**, 5, 4057.
4. Yao, B.; Liang, Z.; Niu, T.; Zhang, Y. *J. Org. Chem.* **2009**, 74, 4630.
5. Ylijoki, K. E. O.; Kündig, E. P. *Chem. Commun.* **2011**, 47, 10608.
6. Kiegiel, K.; Jurczak, J. *Tetrahedron Lett.* **1999**, 40, 1009.

7.618
7.601
7.323
7.311
7.275
6.998
6.980
6.963



2.430









8.149
8.146
8.131
8.127
7.773
7.732
7.675
7.653
7.360
7.352
7.343
7.337
7.272
7.264
7.256
7.238

3.359






7.953
7.935
7.894
7.874
7.660
7.642
7.623
7.548
7.529
7.510
7.400
7.380



2a

3.239


2.455




2.07
1.99
1.05
2.10
2.04


3.00


3.02







2a







2b




7.938
7.923
7.905
7.890
7.657
7.643
7.629
7.544
7.530
7.515
7.385
7.370
7.258


5.781
5.770
5.760
5.747
5.737
5.727
5.266
5.232
5.172
5.152


4.353
4.342

2.460




2c







2c





7.923
7.904
7.769
7.749
7.635
7.617
7.598
7.512
7.493
7.474
7.336
7.316
7.163
7.143
7.009
6.989

2.445
2.336





2d








2d
















2f




















2h







2i













2j









2k

186.95
166.43
148.48
145.77
131.55
130.47
130.17
129.69
129.43
129.11
129.06
128.86
77.32
77.00
76.68
21.76


134.28
133.80
133.75

131.55
130.47
130.17
129.69
129.43
129.11
129.06
128.86



7.951
7.933
7.662
7.643
7.625
7.529
7.509
7.484
7.468
7.383
7.377
7.369
7.360

3.400



1.94

1.09


1.90

3.11


2.02


3.00


f1 (ppm)



21








2m

— 187.38

— 166.44


136.02
134.78
133.12
132.45
132.42
130.44
130.42
130.39
130.10
129.59
128.95

77.32
77.00
76.68






8.267
7.920
7.905
7.826
7.817
7.681
7.666
7.651
7.541
7.525
7.509

3.413



2n







7.894
7.876
7.872
7.672
7.651
7.635
7.629
7.537
7.517
7.498


4.621
4.601
4.581

4.190
4.169
4.150



2o





2o

— 187.78

— 166.45

— 153.06

— 134.77

— 132.36

— 129.31

— 129.00


— 77.32


— 77.00



— 76.68


— 63.97

— 40.94











5a





5a

